CRISPR Therapeutics (LSE:0VRQ) - Stock Price, News & Analysis

0VRQ Stock Overview

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

About the company

0VRQ fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 54.06% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

CRISPR Therapeutics AG Competitors

Genus

LSE:GNS

UK£1.2b

Oxford Biomedica

LSE:OXB

UK£434.6m

Bioventix

AIM:BVXP

UK£193.1m

Avacta Group

AIM:AVCT

UK£179.3m

Price History & Performance

Summary of all time highs, changes and price drops for CRISPR Therapeutics
Historical stock prices
Current Share Price	US$51.65
52 Week High	US$91.00
52 Week Low	US$43.47
Beta	1.66
11 Month Change	14.55%
3 Month Change	10.27%
1 Year Change	-2.22%
33 Year Change	-41.08%
5 Year Change	-4.37%
Change since IPO	30.92%

Recent updates

Shareholder Returns

	0VRQ	GB Biotechs	GB Market
7D	3.2%	-6.1%	-1.3%
1Y	-2.2%	-17.6%	8.0%

Return vs Industry: 0VRQ exceeded the UK Biotechs industry which returned -17.6% over the past year.

Return vs Market: 0VRQ underperformed the UK Market which returned 8% over the past year.

Price Volatility

Is 0VRQ's price volatile compared to industry and market?
0VRQ volatility
0VRQ Average Weekly Movement	5.4%
Biotechs Industry Average Movement	8.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.8%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0VRQ has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0VRQ's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	407	Sam Kulkarni	www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
0VRQ fundamental statistics
Market cap	US$4.41b
Earnings (TTM)	-US$239.59m
Revenue (TTM)	US$202.83m

21.7x

P/S Ratio

-18.4x

P/E Ratio

Is 0VRQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0VRQ income statement (TTM)
Revenue	US$202.83m
Cost of Revenue	US$463.89m
Gross Profit	-US$261.06m
Other Expenses	-US$21.47m
Earnings	-US$239.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.81
Gross Margin	-128.71%
Net Profit Margin	-118.13%
Debt/Equity Ratio	0%

How did 0VRQ perform over the long term?

See historical performance and comparison

0VRQ Stock Overview

Rewards

Risk Analysis

CRISPR Therapeutics AG Competitors

LSE:GNS

UK£1.2b

LSE:OXB

UK£434.6m

AIM:BVXP

UK£193.1m

AIM:AVCT

UK£179.3m

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 22% undervalued after recent price drop

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 22% undervalued after recent price drop

New minor risk - Shareholder dilution

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

New minor risk - Share price stability

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Now 23% undervalued after recent price drop

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Now 20% undervalued

Full year 2022 earnings released: US$8.36 loss per share (vs US$4.97 profit in FY 2021)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

Third quarter 2022 earnings released: US$2.24 loss per share (vs US$1.67 loss in 3Q 2021)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

Now 22% undervalued after recent price drop

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Investor sentiment deteriorated over the past week

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell Malignancies

Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$10.01 (vs US$1.30 loss in 2Q 2020)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy

First quarter 2021 earnings released: US$1.51 loss per share (vs US$1.15 loss in 1Q 2020)

Shareholder Returns

Price Volatility

About the Company

CRISPR Therapeutics AG Fundamentals Summary

21.7x